 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || eclitasertib (DNL758) / Denali Therap, Sanofi
Trial completion date, Trial primary completion date: RESOLUTE: Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (clinicaltrials.gov) - Nov 18, 2023
P2, N=182, Recruiting, Sponsor: Sanofi
Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Jun 2025 --> Nov 2025
- ||| eclitasertib (DNL758) / Denali Therap, Sanofi
Trial completion: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Jun 28, 2023
P2, N=78, Completed, Sponsor: Sanofi
Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Jun 2025 --> Nov 2025 Active, not recruiting --> Completed
- || eclitasertib (DNL758) / Denali Therap, Sanofi
Enrollment closed, Trial completion date, Trial primary completion date: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Mar 30, 2023
P2, N=78, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Jun 2023 | Trial primary completion date: Sep 2023 --> May 2023
- || eclitasertib (DNL758) / Denali Therap, Sanofi
Trial completion date, Trial primary completion date: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Feb 14, 2023
P2, N=88, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Jun 2023 | Trial primary completion date: Sep 2023 --> May 2023 Trial completion date: Jul 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Sep 2023
- |||| eclitasertib (DNL758) / Denali Therap, Sanofi
New P2 trial: RESOLUTE: Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (clinicaltrials.gov) - Oct 20, 2022
P2, N=182, Recruiting, Sponsor: Sanofi
- || eclitasertib (DNL758) / Denali Therap, Sanofi
Trial completion date, Trial primary completion date: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Sep 23, 2022
P2, N=88, Recruiting, Sponsor: Sanofi
Trial completion date: Jul 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Sep 2023 Trial completion date: Mar 2023 --> Jul 2023 | Trial primary completion date: Feb 2023 --> Jun 2023
- || eclitasertib (DNL758) / Denali Therap, Sanofi
Trial completion date, Trial primary completion date: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Dec 9, 2021
P2, N=88, Recruiting, Sponsor: Sanofi
Trial completion date: Mar 2023 --> Jul 2023 | Trial primary completion date: Feb 2023 --> Jun 2023 Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Apr 2022 --> Nov 2022
- || eclitasertib (DNL758) / Denali Therap, Sanofi
Trial completion date, Trial primary completion date: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Aug 18, 2021
P2, N=88, Recruiting, Sponsor: Sanofi
Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Apr 2022 --> Nov 2022 Trial completion date: Jan 2022 --> May 2022 | Trial primary completion date: Dec 2021 --> Apr 2022
- eclitasertib (DNL758) / Denali Therap, Sanofi
[VIRTUAL] Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19 () - Jul 29, 2021 - Abstract #ERS2021ERS_3122;
P1b
Trial completion date: Jan 2022 --> May 2022 | Trial primary completion date: Dec 2021 --> Apr 2022 These preliminary results indicate the need for a larger confirmatory trial to further assess clinically significant effects.
- ||| eclitasertib (DNL758) / Denali Therap, Sanofi
Enrollment open: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Apr 4, 2021
P2, N=88, Recruiting, Sponsor: Sanofi
These preliminary results indicate the need for a larger confirmatory trial to further assess clinically significant effects. Not yet recruiting --> Recruiting
- |||| eclitasertib (DNL758) / Denali Therap, Sanofi
New P2 trial: CLEan: Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Mar 3, 2021
P2, N=88, Not yet recruiting, Sponsor: Sanofi
- ||| eclitasertib (DNL758) / Denali Therap, Sanofi
Trial completion, Immunomodulating: A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 (clinicaltrials.gov) - Oct 29, 2020
P1b, N=68, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || eclitasertib (DNL758) / Denali Therap, Sanofi
Enrollment closed, Immunomodulating: A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 (clinicaltrials.gov) - Oct 6, 2020
P1b, N=67, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| DNL758 / Denali Therap, Sanofi
Clinical: Demiurge AI-based #covid19 #clinicaltrials outcome predictions put to the public test (142_2020): FAILURE for #SAR443122 / NCT04469621 / @sanofi $SNY (Twitter) - Sep 13, 2020
P1b
- ||| eclitasertib (DNL758) / Denali Therap, Sanofi
Enrollment open, Immunomodulating: A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 (clinicaltrials.gov) - Jul 20, 2020
P1b, N=67, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| eclitasertib (DNL758) / Denali Therap, Sanofi
New P1 trial, Immunomodulating: A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 (clinicaltrials.gov) - Jul 13, 2020
P1b, N=67, Not yet recruiting, Sponsor: Sanofi